Compare Dyne Therapeutics Inc. Common Stock (DYN) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs 22nd Century Group Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while 22nd Century Group Inc trades at $0.65 (market cap $464.52K). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 6049.3× 22nd Century Group Inc's market cap, and 22nd Century Group Inc is more actively traded (16,668 versus 2,195,902). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| DYN | XXII | |
|---|---|---|
Market Cap | $2.81B | $464.52K |
Volume | 2,195,902 | 16,668 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $483.00 |
52-Week Low | $14.60 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $2.13B | -$3.84M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
